BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311’s Superior Market Potential Over Pemgarda

Group 1 - Invivyd Inc. (NASDAQ:IVVD) is recognized as a promising biotech penny stock, with BTIG analyst Thomas Shrader initiating coverage with a Buy rating and a $10 price target, highlighting the company's expertise in antibody production [1][3] - The company announced significant regulatory progress for its investigational monoclonal antibody VYD2311, receiving Fast Track designation from the US FDA for COVID-19 prevention in at-risk individuals [2][3] - Invivyd has launched a pivotal Phase 3 clinical trial for VYD2311, which will assess its safety and efficacy in preventing symptomatic COVID-19 among approximately 1,770 participants, with results expected in mid-2026 [3] Group 2 - Invivyd focuses on developing antibody-based solutions for infectious diseases, positioning itself within the biopharmaceutical sector in the US [4]